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Abstract
Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and
children by WHO guidelines. Nevertheless, several cases of haemolytic anaemia due to i.v. artesunate treatment
have been reported. This paper describes the case of an HIV-infected patient with severe falciparum malaria who
was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.
The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where
he had been working. The blood examination revealed acute renal failure, thrombocytopaenia and hypoxia. Blood
for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by
nested-PCR. Severe malaria according to the laboratory WHO criteria was diagnosed. A treatment with quinine and
doxycycline for the first 12 hours was initially administered, followed by arthemeter/lumefantrine (Riamet
®) for a
further three days. At day 10, a diagnosis of severe haemolytic anaemia was made (Hb 6.9 g/dl, LDH 2071 U/l).
Hereditary and autoimmune disorders and other infections were excluded through bone marrow aspiration, total
body TC scan and a wide panel of molecular and serologic assays. The patient was treated by transfusion of six
units of packed blood red cell. He was discharged after complete remission at day 25. At present, the patient is in
a good clinical condition and there is no evidence of haemolytic anaemia recurrence.
This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine. Further
research is warranted to better define the adverse events occurring during combination therapy with artemisinin
derivatives.
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Background
Artemisinins were discovered in 1971 from a herb,
Artemisia annua, known in the past for their activity
against intermittent fever [1]. Now, artemisinin and its
derivatives have become essential components of arte-
misinin-based combination therapy (ACT) [2]. Intrave-
nous (i.v.) artesunate is the recommended first-line
treatment of severe falciparum malaria in adults and
children, including cerebral malaria, because they pro-
duce rapid parasite/fever clearance, show fewer adverse
effects, and have not been associated with occurrence
of less resistance [3,4]. The World Health Organiza-
tion’s (WHO) up-to-date guidelines recommend arte-
sunate as the treatment of choice for adults and
children with severe malaria [5]. However, quinine is
still the primary treatment for severe non-multidrug
resistant Plasmodium falciparum malaria in Europe
because i.v. artesunate is not registred for this indica-
tion. This paper describes the occurrence of a case of
haemolytic anaemia in an HIV-infected patient with
falciparum malaria treated with intravenous (i.v.) qui-
nine and doxycycline for the first 12 hours and then
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A 34-year-old man presented with a seven-day history of
fever, headache, and arthromyalgia after returning from
Central African Republic. He is Italian and he had been
working for governmental and non-governmental orga-
nizations for several years. His past medical history
included HIV infection known since October 2010 with
no anti-retroviral treatment. At admission on 18 July,
2011, the physical examination revealed prostration,
severe obesity (BMI 42), pallor, shallow tachypnoic
breathing, and hepato-splenomegaly. Blood examinations
showed acute renal failure (creatinine 3.29 mg/dl), anae-
mia (Hb 7.4 g/dl), thrombocytopaenia (PLT 17000), glu-
cose 88 mg/dl, AST 108 U/l, ALT 33 U/l, bilirubin total
2.9 mg/dl, bilirubin direct 1.5 mg/dl, albumin 2,5 g/dl,
G6PDH 16 U/gHb, hypoxia and metabolic acidosis (pH
7.35, pO2 62 mmHg, HCO3
- 16.5 mmol/l) (see Table
1). Polymerase Chain Reaction (PCR) and light micro-
scopy on peripheral blood smear detected P. falciparum
with a 6% parasitaemia. Severe malaria, according to
WHO criteria (hyperparasitaemia, metabolic acidosis,
renal impairment), was diagnosed [5].
The patient was initially treated with i.v. quinine load-
ing dose (20 mg/kg, 1500 mg) in combination with oral
doxycycline (100 mg) for the first 12 hours followed by
oral fixed-dose co-formulated artemether/lumefantrine
(Riamet
®) for a further three days. At admission, the
blood test detected moderate-severe anaemia (Hb 7.4 g/
dl and HCT 22%) and a transfusion with one unit of
packed red blood cells (RBC) was prescribed. Because of
the persistence of the anaemia, the patient was trans-
fused with a further RBC transfusion on day 4 (Hb 6.7
g/dl and HCT 20%). Parasite clearance time was 72
hours. Renal and pulmonary functions immediately
improved but fever was still reported up to 28 July,
when the diagnosis of severe haemolytic anaemia was
performed (Hb 6.9 g/dl, haptoglobin < 7.19 mg/dl, reti-
culocytes 4.8%, LDH 2071 U/l). The patient was trans-
fused with an additional four packed blood transfusions
on two different days.
Direct and indirect anti-globulin tests, cold agglutinin
test, and auto-immune assays were all negative; PCR and
antibody detection for chikungunya, dengue, serology for
B19 Parvovirus, Leishmania species, Mycoplasma pneu-
moniae, Chlamydia pneumoniae, Mycobacterium tuber-
culosis complex, atypical mycobacteria, Salmonella typhi
and paratyphi, Trypanosoma spp., Toxoplasma gondii,
and Treponema pallidum were all negative; antigens of
Cryptococcus neoformans were not detectable; PCR and
peripheral blood smears for Plasmodium species were







Day 17 Day 25
12 Aug
Normal values
Glucose, g/dl 88 0.97 70-1.10
Urea, g/l 2.16 0.33 0.10-0.50
Creatinine, mg/dl 3.29 0.65 0.5-1.4
Potassium, mEq/l 3.5 4.9 3.6-5.5
Bilirubin total/direct, mg/dl 2.9/1.5 1.4/0.7 1.6/0.6 1.9/0.8 < 1.2/0.3
AST/ALT, U/l 108/33 32/26 40/23 < 40
Erythrocytes,1 0
6/mm3 2.43 2.6 2.16 1.81 2.91 3.8-6.1
Haemoglobin, g/dl 7.4 8 6.9 5.9 9.6 12-18
Haematocrit, % 22 24 20 18 29 36-52
Reticulocytes % 4.8 8.2 0.5-2.0
Platelets, 10
3/mmc 17 114 127 98 152 80-400
White blood cells, 10
3/mmc 5.1 6.7 5.3 2.6 3.5 4.3-10.8
Neutrophils % 75.5 41.1 23.1 31.6 36.6 40-75
Lymphocytes % 20 42.7 62 49 41.2 20-51
CD4 cells/mmc (%) 569 (23.2) (36-44)
HIV-RNA, cp/ml 161769
Erythrocyte Sedimentation Rate, mm/hr 122 > 140 > 140 < 15
C-Reactive proteine mg/dl 21 4.7 < 0.6
Thick and thin smears Pos Neg, day 3 Neg
PCR for Plasmodium falciparum Pos Neg, day 3 Neg
Parasitaemia 6%
Coombs test direct/indirect neg/neg neg/neg
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tive for infectious agents and lympho-proliferative dis-
eases. A total body CT scan reported splenomegaly. After
significant improvement of his clinical condition, the
patient was discharged on 12 August (Hb 9.6 g/dl). Five
weeks after discharge, haemoglobin, haematocrit, reticu-
locytes count were all within normal values (see Table 1).
The patient is now in good clinical condition and back to
his daily working life with no evidence of haemolytic
anaemia recurrence.
Written informed consent was obtained from the
patient for publication of this case report.
Discussion
There are multiple causes of haemolytic anaemia, and
the clinical presentation can differ depending on the
etiology. Haemolysis may be extravascular due to auto-
immune disorders or to hereditary spherocytosis, intra-
vascular (e.g. associated to insertion of prosthetic
cardiac valves, G6PDH deficiency, thrombotic thrombo-
cytopenic purpura or disseminated intravascular coagu-
lation), or intramedullary-related due to pernicious
anaemia and thalassemia major. The haemolytic disorder
can be hereditary as in case of G6PDH deficiency [6],
haemoglobinopathies and RBC membrane abnormalities,
or acquired, as in the case of immune disorders [7],
exposure to toxic chemicals and drugs [8], paroxysmal
nocturnal haemoglobinuria [9], traumatic and microan-
giopathic haemolysis, hypersplenism or infections [10].
In this report, hereditary and auto-immune disorders
were excluded. Infectious agents other than malaria
were searched for with a wide panel of molecular and
serologic assays and through bone marrow examination.
All the results were negative. CT scan and bone marrow
analysis excluded lymphoproliferative disorders. Malaria
was treated with i.v. quinine and doxycycline for the
first 12 hours only, followed by Riamet
® for 72 hours.
At day 10 a diagnosis of severe haemolytic anaemia was
established and it was treated by transfusion with six
units of packed red blood cells. The duration of haemo-
lysis was 15 days. The patient was discharged on 12
August after complete remission from severe malaria
and haemolytic anaemia.
There are few cases described in literature of haemoly-
tic anaemia during or after treatment with i.v. artesunate
alone or combined with mefloquine. Yasouka et al
reported the case of a Nigerian male with severe P. falci-
parum malaria initially treated with mefloquine. After
one day of treatment, because of the worsening clinical
condition of the patient and the increase of the parasitae-
mia, therapy with i.v. artesunate was initiated. Parasite
clearance was obtained within 20 hours after the first
administration of artesunate, but fever persisted for a
further seven days and haemolytic anaemia was observed,
requiring blood transfusion [11]. Yoshizawa et al
described the case of a young woman with P. falciparum
malaria who was successfully treated with i.v. artesunate,
but showed worsening anaemia after artesunate adminis-
tration [12]. Itoda et al observed severe haemolytic anae-
mia and jaundice on day 11 after i.v. artesunate
administration in a 68-year-old Japanese woman affected
by severe malaria [13]. Recently, Zoller et al reported a
series of 25 travellers with severe malaria treated with i.v.
artesunate. Among them, six patients developed haemo-
lytic anaemia week after treatment possibily related to
artesunate or had persistent signs of haemolytic activity
until six weeks after the first dose of i.v. artesunate [14].
In this case series, patients with post-treatment haemoly-
sis had received a higher cumulative dose of i.v. artesu-
nate and were treated for longer periods.
This appears to the first reported case of haemolytic
anaemia after treatment with oral fixed-dose co-formu-
lated artemether/lumefantrine. The observation supports
the hypothesis that haemolysis might occur as a conse-
quence of artemether treatment. Efficacy and safety pro-
files of i.v. artesunate and ACT should be prospectively
evaluated, and patients should be monitored for signs of
haemolysis after parasitological cure.
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